SUPT16HP1

Across TCGA pan-cancer cohorts, SUPT16HP1 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated SUPT16HP1 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SUPT16HP1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUPT16HP1 expression acts as an unfavorable survival marker, although some lineages such as CESC and LAML show a favorable association.

STAD, ACC, and CESC are the cancer types where SUPT16HP1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.470	0.638	.001	56	view →
ACC	DFS	Median	All	0.389	0.740	<.001	42	view →
CESC	OS	Median	II,III,IV	0.683	0.276	<.001	42	view →
HNSC	OS	Median	All	0.466	0.721	<.001	36	view →
LAML	DFS	Quartile	All	0.499	0.222	.002	36	view →
UVM	DFS	Median	III,IV	0.280	0.576	.016	29	view →
KIRC	OS	Quartile	All	0.730	0.510	.003	23	view →
BRCA	DFS	Tertile	IV	0.597	0.207	.010	20	view →
GBM	DFS	Median	All	0.413	0.175	<.001	20	view →
UCS	DFS	Tertile	IV	0.981	0.361	.024	18	view →
COAD	OS	Median	IV	0.389	0.696	.003	13	view →
LUSC	DFS	Quartile	III,IV	0.359	0.994	.016	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

SUPT16HP1–STAD (DFS)

Open the STAD breakdown →